Mark Cuban Tackles Custom Rare Disease Drugs

Mark Cuban is bringing his cost-cutting playbook to one of medicine's most expensive frontiers: custom-made genetic treatments for rare diseases.

His company Cost Plus Drugs, which has spent five years making generic medications like chemotherapy cheaper, recently started manufacturing personalized genetic medicines at its Dallas factory. These aren't your typical mass-produced pills.

One shipment contained DNA-like molecules designed specifically to fix a genetic mutation destroying a single patient's neurons. Another carried molecules developed to stop a rare disease that causes adults to progressively lose muscle control.

Cuban says the decision was straightforward. "It was an obvious chance for us to help those in that unfortunate situation," he wrote in an email to STAT News.

The move could reshape how patients access ultra-rare disease treatments. Traditional pharmaceutical companies often struggle to make custom therapies financially viable when they're designed for just one person. The result? Families face crushing costs or can't access treatments at all.

Cost Plus Drugs built its reputation on transparency, adding only a 15% markup to generic drug production costs. Now Cuban is testing whether that same model can work for cutting-edge genetic medicines that currently exist in a high-priced, specialized market.

The factory is working with California chemists and Dutch researchers to produce these personalized treatments. Each medicine is crafted to target a specific patient's unique genetic mutation.

The Ripple Effect

Cuban's expansion into rare disease treatments arrives at a critical moment. More families are discovering their loved ones have treatable genetic conditions, but the price tags often reach hundreds of thousands or millions of dollars.

If Cost Plus Drugs succeeds, it could open the door for dozens of patients currently priced out of life-changing therapies. Other manufacturers might follow suit, creating competition that drives prices down across the industry.

The work also validates a growing movement toward individualized medicine. As genetic testing becomes more common, doctors are identifying more rare mutations that could be treated with custom therapies if the production costs weren't prohibitive.

Cuban's Dallas facility now stands at the intersection of two major healthcare challenges: making medicine affordable and making it personal. Early results will show whether his cost-cutting approach can scale to medicine's most complex treatments.

For families watching their loved ones battle ultra-rare diseases, Cuban's latest venture offers something that's been in short supply: hope that financial barriers won't determine who gets to live.